BIO-key International, Inc.

The stock remains in a long-term downtrend, still below its 200-day average of 6.2464 even after a recent rebound. The setup is improving off the 52-week low of 3.1, but the share price is still far from the 52-week high of 13.8, so the regime is recovery rather than confirmation.

Street sentiment is cautiously constructive: the consensus is Buy with a 4 target, and the lone published target sits well above the current trading range. No recent rating changes or target revisions stand out, so the call is anchored by one bullish view rather than broad conviction.

The next print follows a mixed beat history, with 3 beats in the last 7 quarters and a sharp 78.3% upside surprise in the most recent reported quarter. Estimates still point to losses, with 2026 EPS at -2.3 versus -5.0 for 2025, so shareholders should watch whether revenue growth and margin discipline keep narrowing losses.

Insider activity leans positive, with net buying alongside several automatic awards to senior executives. The only discretionary signal is CEO Michael DePasquale’s open-market purchases in August and September 2025, which were followed by additional awards across the leadership team in late 2025 and mid-2026.

Profitability remains weak, but revenue is growing and the balance sheet is not stretched. Gross margin is 77.3%, revenue grew 33.5% year over year, and the company ended fiscal 2025 with $2.69 million in cash versus $703,626 of debt and $1.99 million in net cash.

BKYI sits in a niche identity and biometric security lane where product breadth and government/commercial exposure matter more than scale. Versus software peers, the valuation is still depressed: the market cap is about $5.4 million, while the consensus target implies a much higher recovery case.